search
Back to results

Changes in Microbiota and Quality of Life in IBS

Primary Purpose

IBS - Irritable Bowel Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
a supplement containing 2'-fucosyllactose (2'-FL)
Placebo Supplement
Sponsored by
National University of Natural Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IBS - Irritable Bowel Syndrome

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults age 18-70 years (inclusive)
  • Existing diagnosis of IBS
  • Willing to take the 2'-FL-containing dietary supplement (or a control supplement) three times per day for 6 weeks
  • Willing to attend 4 in-person study visits
  • Willing to collect 3 stool samples at home
  • Willing to periodically monitor stool form/consistency (and log the information on a diary)
  • Willing to complete IBS symptom focused questionnaires
  • Willing to refrain from making changes in dietary supplements and medications for the duration of the study
  • Willing to maintain current dietary pattern for the duration of the study
  • Willing to maintain current exercise pattern for the duration of the study
  • Able to speak, read, and understand the English language
  • Able to provide written informed consent

Exclusion Criteria:

  • Do not have an active primary care provider or specialist managing their IBS
  • Initiation of or changes to supplements or medications within 2 weeks prior to screening and/or enrollment (changes include stopping or changing the dose of supplements or medications)
  • Intake of prebiotic or fiber supplement(s) (current intake or intake within 2 weeks prior to screening and/or enrollment)
  • Intake of probiotic supplement(s) (current intake or intake within 2 weeks prior to screening and/or enrollment)
  • Use of antibiotic, antiparasitic, or antifungal medications orally or intravenously (current use or use within 2 weeks prior to screening and/or enrollment)
  • Initiation of or changes to an exercise regimen within 2 weeks prior to screening and/or enrollment
  • Initiation of or changes to a food plan within 2 weeks prior to screening and/or enrollment
  • Current involvement or within 2 weeks prior to screening and/or enrollment of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR)
  • Current or previous history of chronic gastrointestinal illness other than IBS (e.g. inflammatory bowel disease, celiac disease, diverticulitis, cirrhosis, hepatitis, etc.)
  • History of gastrointestinal surgery other than appendectomy (e.g. weight loss surgery, cholecystectomy, splenectomy, etc.)
  • Major medical or surgical event requiring hospitalization (for any reason other than a minor scheduled medical procedure) within 3 months prior to screening
  • Cancer diagnosis or treatment within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix)
  • Currently participating in another interventional research study or participated in another interventional study within 2 weeks prior to screening
  • Known intolerance or allergy to ingredients that may be in the study supplement or control supplement (Collinsonia root, beet root, okra, date powder, sucanat, rice hull concentrate, rice bran extract, cellulose, calcium stearate, calcium phosphate, gum arabic, or a trace amount of lactose)
  • Women who are lactating, pregnant or planning pregnancy within the next 3 months

Sites / Locations

  • National University of Natural MedicineRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Investigational supplement

Placebo supplement

Arm Description

Participants in this arm will take a supplement containing 2'-fucosyllactose (2'-FL)

Participants in this arm will take a placebo supplement

Outcomes

Primary Outcome Measures

F. Prausnitzii abundance
F. Prausnitzii abundance will be measured in stool via 16s RNA sequencing and quantified

Secondary Outcome Measures

F. Prausnitzii relative abundance
F. Prausnitzii abundance will be measured in stool via 16s RNA sequencing and the proportion to other organisms calculated
Bifidobacterium spp. relative abundance
Bifidobacterium spp. relative abundance in stool will be measured via 16s RNA sequencing and the proportion to other organisms calculated
Alpha diversity of the microbiota
Alpha diversity is a measure of overall diversity of organisms within in a stool sample
Beta diversity of the microbiota
Beta diversity is a measure of overall diversity of organisms between stool samples in the cohort of participants
IBS-Severity Scoring System
Validated instrument that quantified patient-reported IBS severity
IBS-Adequate Relief from Symptoms
Validated instrument that measures patient-reported relief from IBS symptoms
Bristol Stool Form Scale
7-point scale used qualitatively assessing form of stool

Full Information

First Posted
February 23, 2022
Last Updated
March 22, 2023
Sponsor
National University of Natural Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05266287
Brief Title
Changes in Microbiota and Quality of Life in IBS
Official Title
Evaluating Changes in Microbiota Composition and Quality of Life in Irritable Bowel Syndrome: A Randomized, Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 15, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National University of Natural Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary research question to be addressed is: Does a 2'-FL-containing dietary supplement impact stool microbiota composition in adults with IBS? The primary measure for determining potential impacts of the 2'-FL-containing dietary supplement on stool microbiota composition is stool abundance of Faecalibacterium prausnitzii, a commensal intestinal bacteria. Additional measures related to determining potential impacts of the 2'-FL-containing dietary supplement on gut microbiota composition are stool levels of additional commensal intestinal bacteria and measures of intestinal microbial diversity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IBS - Irritable Bowel Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Investigational supplement
Arm Type
Experimental
Arm Description
Participants in this arm will take a supplement containing 2'-fucosyllactose (2'-FL)
Arm Title
Placebo supplement
Arm Type
Placebo Comparator
Arm Description
Participants in this arm will take a placebo supplement
Intervention Type
Dietary Supplement
Intervention Name(s)
a supplement containing 2'-fucosyllactose (2'-FL)
Intervention Description
Participants will be asked to take a commercially available dietary supplement containing 833 mg of 2'-FL, 220 mg of a blend of organic beet root and okra fruit, 100 mg of Collinsonia root, 37.5 mg organic rice hull concentrate, and 14 mg calcium stearate.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Supplement
Intervention Description
Participants will be asked to take a placebo supplement containing 510.9 mg organic sucanat, 385.4 mg calcium phosphate, 304.7 mg cellulose, 143.4 mg date powder, 39.4 mg rice bran powder, 9.0 mg gum arabic, and 7.2 mg calcium stearate.
Primary Outcome Measure Information:
Title
F. Prausnitzii abundance
Description
F. Prausnitzii abundance will be measured in stool via 16s RNA sequencing and quantified
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
F. Prausnitzii relative abundance
Description
F. Prausnitzii abundance will be measured in stool via 16s RNA sequencing and the proportion to other organisms calculated
Time Frame
6 weeks
Title
Bifidobacterium spp. relative abundance
Description
Bifidobacterium spp. relative abundance in stool will be measured via 16s RNA sequencing and the proportion to other organisms calculated
Time Frame
6 weeks
Title
Alpha diversity of the microbiota
Description
Alpha diversity is a measure of overall diversity of organisms within in a stool sample
Time Frame
6 weeks
Title
Beta diversity of the microbiota
Description
Beta diversity is a measure of overall diversity of organisms between stool samples in the cohort of participants
Time Frame
6 weeks
Title
IBS-Severity Scoring System
Description
Validated instrument that quantified patient-reported IBS severity
Time Frame
6 weeks
Title
IBS-Adequate Relief from Symptoms
Description
Validated instrument that measures patient-reported relief from IBS symptoms
Time Frame
6 weeks
Title
Bristol Stool Form Scale
Description
7-point scale used qualitatively assessing form of stool
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults age 18-70 years (inclusive) Existing diagnosis of IBS Willing to take the 2'-FL-containing dietary supplement (or a control supplement) three times per day for 6 weeks Willing to attend 4 in-person study visits Willing to collect 3 stool samples at home Willing to periodically monitor stool form/consistency (and log the information on a diary) Willing to complete IBS symptom focused questionnaires Willing to refrain from making changes in dietary supplements and medications for the duration of the study Willing to maintain current dietary pattern for the duration of the study Willing to maintain current exercise pattern for the duration of the study Able to speak, read, and understand the English language Able to provide written informed consent Exclusion Criteria: Do not have an active primary care provider or specialist managing their IBS Initiation of or changes to supplements or medications within 2 weeks prior to screening and/or enrollment (changes include stopping or changing the dose of supplements or medications) Intake of prebiotic or fiber supplement(s) (current intake or intake within 2 weeks prior to screening and/or enrollment) Intake of probiotic supplement(s) (current intake or intake within 2 weeks prior to screening and/or enrollment) Use of antibiotic, antiparasitic, or antifungal medications orally or intravenously (current use or use within 2 weeks prior to screening and/or enrollment) Initiation of or changes to an exercise regimen within 2 weeks prior to screening and/or enrollment Initiation of or changes to a food plan within 2 weeks prior to screening and/or enrollment Current involvement or within 2 weeks prior to screening and/or enrollment of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR) Current or previous history of chronic gastrointestinal illness other than IBS (e.g. inflammatory bowel disease, celiac disease, diverticulitis, cirrhosis, hepatitis, etc.) History of gastrointestinal surgery other than appendectomy (e.g. weight loss surgery, cholecystectomy, splenectomy, etc.) Major medical or surgical event requiring hospitalization (for any reason other than a minor scheduled medical procedure) within 3 months prior to screening Cancer diagnosis or treatment within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix) Currently participating in another interventional research study or participated in another interventional study within 2 weeks prior to screening Known intolerance or allergy to ingredients that may be in the study supplement or control supplement (Collinsonia root, beet root, okra, date powder, sucanat, rice hull concentrate, rice bran extract, cellulose, calcium stearate, calcium phosphate, gum arabic, or a trace amount of lactose) Women who are lactating, pregnant or planning pregnancy within the next 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anders Gundersen, MS
Phone
503-552-1752
Email
agundersen@nunm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ryan Bradley, ND, MPH
Organizational Affiliation
National University of Natural Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
National University of Natural Medicine
City
Portland
State/Province
Oregon
ZIP/Postal Code
97201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anders Gundersen, MS
Email
agundersen@nunm.edu

12. IPD Sharing Statement

Learn more about this trial

Changes in Microbiota and Quality of Life in IBS

We'll reach out to this number within 24 hrs